as mentioned in In the second year of the study, the results were more pronounced, with a 35 percent reduction in heart attack risk and a 24 percent decrease in stroke risk.
The trial’s primary composite goal included need for artery clearing procedures and hospitalization due to chest pains from angina in addition to heart attack, stroke and death.
“To see a more than 20 percent risk reduction for stroke was really exciting,” said Amgen research chief Sean Harper.
Most trial subjects had had a prior heart attack or stroke.
On that measure, the overall risk reduction was 15 percent, primarily due to no difference from placebo in angina hospitalizations.
as declared in Image Source/iStockphotoPricey new cholesterol drug scrapes by in heart risk studyA year and a half after its feted approval, a new cholesterol drug has passed a key test.
“The open question was, ‘Does this way of lowering [cholesterol] reduce risk of coronary heart disease,’” says Sekar Kathiresan, a cardiologist at the Massachusetts General Hospital in Boston and the Broad Institute in Cambridge, Massachusetts, who was not involved in the study.
Repatha showed a measurable—if modest—benefit in reducing cardiovascular events such as heart attacks and stroke.
There was no question that Repatha, an antibody drug developed by Amgen, could provide stunning drops in cholesterol for people who have already maxed out the benefits of decades-old statin drugs.
That was good enough for the U.S. Food and Drug Administration (FDA), which approved both drugs in 2015.
Genome-based cholesterol drug boosts heart health : Nature News & Comment
as declared in But any new cholesterol drug faces stiff competition from cheaper statins, which have been used to control LDL levels for decades.
On another measure that also included hospitalizations for conditions that cause reduced blood flow to the heart, evolocumab reduced the risk by 15%.
Some analysts say that demonstrating a statistically significant heart-health benefit would not be enough to ensure the PCSK9 drug’s status as the next big thing.
Juan Gaertner/Science Photo LibraryFor years, medical researchers have hoped that a burgeoning class of cholesterol drugs targeting a protein called PCSK9 could be the next generation of blockbuster treatments.
Now, a large clinical trial has demonstrated that this approach can lower the risk of heart disease.
This content may collect you by Jack Oliver